NPC's John O'Brien to Speak at the Financial Times Live U.S. Pharma and Biotech Summit

  • May 16, 2024 - 11:40am - 12:20pm

Join NPC President and CEO John O'Brien in NYC (or virtually from around the world) on May 16 for a panel on "Solving the U.S. Drug Pricing Problem."

FTSummit-Crop2

At the Financial Times Live U.S. Pharma and Biotech Summit in New York City on Thursday, May 16, NPC President and CEO John O'Brien, PharmD, MPH, will join a panel on “Solving the U.S. Drug Pricing Problem.” Dr. O'Brien will be joined by Sarah Emond, President and CEO, the Institute for Clinical and Economic Review, and Greg Baker, CEO, AffirmedRx. (More panelists to come.)

2024 is a pivotal year for the U.S. healthcare sector. America remains a global leader in life sciences investment and innovation, but access to healthcare in the US is uneven, regulations are uncertain, and the presidential election poses risks to Pharma. 

  • What can stakeholders do to address falling life expectancy in the US?
  • How is AI being plugged into discovery models?
  • Are pharma workforces ready for a new generation of American talent?

The Financial Times Live U.S. Pharma and Biotech Summit returns to New York in May 2024, partnered with Endpoints News for the first time. Gathering leaders and experts in areas such as drug discovery, clinical development and market access to share insights and connect with each other.

As part of the National Pharmaceutical Council community, you can save 20% off on your in-person and digital pass with discount code FTNPC: https://bit.ly/3TM0B9y #FTPharma

 

 

Panel: Solving the U.S. Drug Pricing Problem

Thursday, May 16 | 11:40 a.m. – 12:20 p.m. ET | In-Person & Digital | One Liberty Plaza, New York, New York 

The US drug pricing system appears to be in the midst of real reform, with Congress taking action and payers announcing changes to pricing models.

  • Why has drug pricing in the US been change-proof for so long?
  • Are recent reforms already having a significant impact on patient access?
  • Why did it take somebody like Mark Cuban and his Cost Plus Drugs Company to break the logjam?
  • Will driving down costs for generics put supply chains of those medicines at risk? 

Panelists: 

  • Greg Baker, CEO, AffirmedRx
  • Sarah Emond, President and CEO, Institute for Clinical and Economic Review
  • John O'Brien, President and CEO, National Pharmaceutical Council 

 

 

FTSummit-Crop

Learn More & Register

Click the button below to register for the event and/or learn more about sessions and sessions and speakers! Save 20% off your in-person or digital registration with the code FTNPC.

Register Here